Beijing Tiantan Biological Products Corp Ltd (600161) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Tiantan Biological Products Corp Ltd (600161) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥318.80 Million ≈ $46.65 Million USD) by net assets (CN¥14.95 Billion ≈ $2.19 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Beijing Tiantan Biological Products Corp market cap and net worth for the company's overall valuation and market capitalisation.
Beijing Tiantan Biological Products Corp Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Beijing Tiantan Biological Products Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beijing Tiantan Biological Products Corp Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Tiantan Biological Products Corp Ltd ranked by their cash flow conversion efficiency. Explore Beijing Tiantan Biological Products Corp cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Olav Thon Eien
OL:OLT
|
0.000x |
|
Hinge Health, Inc.
NYSE:HNGE
|
0.169x |
|
Jiangxi Hongdu Aviation Industry Co Ltd
SHG:600316
|
0.092x |
|
Hunan Valin Steel Co Ltd
SHE:000932
|
0.033x |
|
New Hope Corporation Ltd
AU:NHC
|
0.071x |
|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
-0.131x |
|
QL Resources Bhd
KLSE:7084
|
0.012x |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NYSE:AMRX
|
0.144x |
Annual Cash Flow Conversion Efficiency for Beijing Tiantan Biological Products Corp Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Tiantan Biological Products Corp Ltd from 1998 to 2024. View Beijing Tiantan Biological Products Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥14.53 Billion ≈ $2.13 Billion |
CN¥819.78 Million ≈ $119.96 Million |
0.056x | -69.94% |
| 2023-12-31 | CN¥12.75 Billion ≈ $1.87 Billion |
CN¥2.39 Billion ≈ $350.26 Million |
0.188x | +89.27% |
| 2022-12-31 | CN¥11.36 Billion ≈ $1.66 Billion |
CN¥1.13 Billion ≈ $164.77 Million |
0.099x | +3.84% |
| 2021-12-31 | CN¥10.27 Billion ≈ $1.50 Billion |
CN¥980.35 Million ≈ $143.46 Million |
0.095x | -17.98% |
| 2020-12-31 | CN¥6.03 Billion ≈ $882.52 Million |
CN¥702.11 Million ≈ $102.74 Million |
0.116x | -6.18% |
| 2019-12-31 | CN¥5.18 Billion ≈ $757.61 Million |
CN¥642.47 Million ≈ $94.01 Million |
0.124x | -20.43% |
| 2018-12-31 | CN¥4.35 Billion ≈ $636.07 Million |
CN¥677.92 Million ≈ $99.20 Million |
0.156x | +127.40% |
| 2017-12-31 | CN¥3.18 Billion ≈ $465.96 Million |
CN¥218.39 Million ≈ $31.96 Million |
0.069x | -60.92% |
| 2016-12-31 | CN¥2.44 Billion ≈ $357.19 Million |
CN¥428.37 Million ≈ $62.68 Million |
0.175x | -17.08% |
| 2015-12-31 | CN¥2.24 Billion ≈ $327.23 Million |
CN¥473.26 Million ≈ $69.25 Million |
0.212x | -1.81% |
| 2014-12-31 | CN¥2.22 Billion ≈ $324.51 Million |
CN¥477.95 Million ≈ $69.94 Million |
0.216x | -17.19% |
| 2013-12-31 | CN¥2.18 Billion ≈ $318.46 Million |
CN¥566.43 Million ≈ $82.89 Million |
0.260x | +7.07% |
| 2012-12-31 | CN¥1.78 Billion ≈ $260.05 Million |
CN¥432.00 Million ≈ $63.22 Million |
0.243x | -0.46% |
| 2011-12-31 | CN¥1.45 Billion ≈ $211.62 Million |
CN¥353.15 Million ≈ $51.68 Million |
0.244x | +50.88% |
| 2010-12-31 | CN¥1.14 Billion ≈ $167.13 Million |
CN¥184.85 Million ≈ $27.05 Million |
0.162x | -65.73% |
| 2009-12-31 | CN¥949.13 Million ≈ $138.89 Million |
CN¥448.23 Million ≈ $65.59 Million |
0.472x | +29.34% |
| 2008-12-31 | CN¥756.97 Million ≈ $110.77 Million |
CN¥276.39 Million ≈ $40.44 Million |
0.365x | +72.54% |
| 2007-12-31 | CN¥725.57 Million ≈ $106.17 Million |
CN¥153.55 Million ≈ $22.47 Million |
0.212x | -2.89% |
| 2006-12-31 | CN¥708.35 Million ≈ $103.65 Million |
CN¥154.36 Million ≈ $22.59 Million |
0.218x | +10.72% |
| 2005-12-31 | CN¥669.09 Million ≈ $97.91 Million |
CN¥131.69 Million ≈ $19.27 Million |
0.197x | +13.83% |
| 2004-12-31 | CN¥636.79 Million ≈ $93.18 Million |
CN¥110.11 Million ≈ $16.11 Million |
0.173x | +64.78% |
| 2003-12-31 | CN¥599.70 Million ≈ $87.76 Million |
CN¥62.93 Million ≈ $9.21 Million |
0.105x | -64.06% |
| 2002-12-31 | CN¥289.04 Million ≈ $42.30 Million |
CN¥84.38 Million ≈ $12.35 Million |
0.292x | +81.90% |
| 2001-12-31 | CN¥289.68 Million ≈ $42.39 Million |
CN¥46.49 Million ≈ $6.80 Million |
0.160x | -6.46% |
| 2000-12-31 | CN¥279.21 Million ≈ $40.86 Million |
CN¥47.90 Million ≈ $7.01 Million |
0.172x | +12.68% |
| 1999-12-31 | CN¥279.67 Million ≈ $40.92 Million |
CN¥42.58 Million ≈ $6.23 Million |
0.152x | +70.68% |
| 1998-12-31 | CN¥265.80 Million ≈ $38.89 Million |
CN¥23.71 Million ≈ $3.47 Million |
0.089x | -- |
About Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamin… Read more